|
|
Volumn 13, Issue 8, 2012, Pages 764-765
|
|
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
EGFR PROTEIN, HUMAN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
TUMOR MARKER;
COST BENEFIT ANALYSIS;
DRUG ANTAGONISM;
DRUG COST;
ECONOMICS;
ENZYMOLOGY;
EVIDENCE BASED MEDICINE;
GENETICS;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
METASTASIS;
MORTALITY;
MUTATION;
NOTE;
PATHOLOGY;
PRACTICE GUIDELINE;
QUALITY ADJUSTED LIFE YEAR;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
EVIDENCE-BASED MEDICINE;
GREAT BRITAIN;
HUMANS;
LUNG NEOPLASMS;
MUTATION;
PRACTICE GUIDELINES AS TOPIC;
PROTEIN KINASE INHIBITORS;
QUALITY-ADJUSTED LIFE YEARS;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
MLCS;
MLOWN;
|
|
EID: 84867301115
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(12)70296-6 Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
